MRD tracking in AML with azacitidine and venetoclax
Part of Blood & lymphatic, Cancer clinical trials.
This study is for adults with newly diagnosed acute myeloid leukemia (AML) who will receive the drugs azacitidine and venetoclax as their first treatment. Researchers will monitor tiny amounts of cancer left after treatment (MRD) to see how it affects survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received treatment for it (except possibly hydroxyurea).
- Your doctor plans to treat you with the combination of azacitidine (a type of chemotherapy) and venetoclax (a targeted therapy) as your first therapy.
- You are not a candidate for strong (intensive) chemotherapy because of your age or other health factors.
- Your AML is not in your brain or spinal cord, and it is not a type called acute promyelocytic leukemia (APL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This trial tests whether the combination of venetoclax and azacitidine can clear small amounts of leukemia cells that remain after initial chemotherapy (called measurable residual disease or MRD). It is for people with acute myeloid leukemia who have MRD before a stem cell transplant.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.